Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

Akari Therapeutics logo
$0.76 -0.05 (-5.82%)
Closing price 08/29/2025 03:57 PM Eastern
Extended Trading
$0.78 +0.02 (+2.50%)
As of 08/29/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Key Stats

Today's Range
$0.76
$0.81
50-Day Range
$0.76
$1.18
52-Week Range
$0.76
$4.00
Volume
26,043 shs
Average Volume
47,099 shs
Market Capitalization
$24.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Akari Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

AKTX MarketRank™: 

Akari Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 305th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akari Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Akari Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.15% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently increased by 17.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Akari Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akari Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.15% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently increased by 17.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Akari Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Akari Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for AKTX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,660.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.06% of the stock of Akari Therapeutics is held by institutions.

  • Read more about Akari Therapeutics' insider trading history.
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKTX Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
See More Headlines

AKTX Stock Analysis - Frequently Asked Questions

Akari Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, AKTX shares have decreased by 37.7% and is now trading at $0.76.

Akari Therapeutics PLC (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $5.00.

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of Akari Therapeutics include Omnia Family Wealth LLC (0.19%).
View institutional ownership trends
.

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

Company Calendar

Last Earnings
3/31/2020
Today
8/30/2025
Next Earnings (Estimated)
9/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKTX
CIK
1541157
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+557.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.03%
Return on Assets
-31.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
0.95

Miscellaneous

Outstanding Shares
32,180,000
Free Float
19,917,000
Market Cap
$24.46 million
Optionable
Not Optionable
Beta
0.22
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:AKTX) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners